The Latest Cardiac and Vascular News
Results from 10 patients enrolled in the PIVOTAL study show that autoregulation enables an appropriate and immediate adaptation of cardiac output to patients’ needs CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic […]
The procedure was performed at UofL Health – Jewish Hospital by University of Louisville physicians in the first cohort of the U.S. Early Feasibility Study PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need […]
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces that it has received final approval from the Patient Protection […]
6 Aeson® artificial hearts marketed to date Enrollment of the first cohort of 3 patients in the EFS1 in the USA finalized Cash position of €58 million at June 30, 2021, covering the Company’s activities through to mid-2022 Videoconference with Stéphane Piat today at 5 pm Paris time PARIS–(BUSINESS WIRE)–Regulatory News: […]
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the third implant of its Aeson® bioprosthetic artificial heart in a commercial setting. This new […]
The implant was performed at UofL Health – Jewish Hospital by University of Louisville physicians within the framework of the U.S. Early Feasibility Study PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by […]
The implant was performed at Hannover Medical School PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the first implant of its Aeson® bioprosthetic […]
The implant, performed at the Azienda Ospedaliera dei Colli hospital in Naples, Italy, represents the first sale for CARMATand paves the way for the Company’s commercial development PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a […]
The implant was performed at Duke University Hospital, one of the largest U.S. cardiology centers PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage […]
The Board of Directors warmly thanks Dr. Philippe Pouletty, Managing Director of Truffle Capital, for his exceptional contribution to the development of the CARMAT project, and proposes the appointment of three new directors, Florent Battistella, David Coti and John B. Hernandez. CARMAT (FR0010907956, ALCAR), the designer and developer of the […]
